Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis Pipeline from the 2023 Annual Report (PDF 0.1 MB)

Show Filters
Showing 109 results
  • NIO752
    Progressive supranuclear palsy
    Neuroscience Phase 1 Tau antagonist
    Lead Indication
  • NZV930
    NZV930, spartalizumab, NIR178
    Solid tumors
    Oncology: Solid Tumors Phase 1 CD73 Antagonist
    Lead Indication
  • OAV101
    Spinal muscular atrophy (SMA) IT administration
    Neuroscience Phase 3 2025 Survival motor neuron (SMN1) gene replacement therapy
    Supplementary Indication
  • OMB157
    Multiple sclerosis, pediatrics
    Neuroscience Phase 3 ≥ 2027 CD20 Antagonist
    Supplementary Indication
  • PHE885
    durcabtagene autoleucel
    4L multiple myeloma
    Oncology: Hematology Phase 2 BCMA cell therapy
    Lead Indication
  • PIT565
    B-cell malignancies
    Oncology: Hematology Phase 1
    Lead Indication
  • PKC412
    Acute myeloid leukemia, pediatrics
    Oncology: Hematology Phase 2 2026 Multi-targeted kinase inhibitor
    Supplementary Indication
  • QEQ278
    Oncology: Solid Tumors Phase 1 NKG2D/-L pathway modulator
    Lead Indication
  • QGE031
    Food allergy
    Immunology Phase 3 ≥ 2027 IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)
    Lead Indication
  • QMF149
    Pediatric Asthma
    In-market Brands and Global Health Phase 3 ≥ 2027 Indacaterol acetate +mometasone furoate
    Supplementary Indication
  • QUC398
    Immunology Phase 2 ADAMTS5 inhibitor
    Lead Indication
  • RHH646
    Immunology Phase 2
    Lead Indication
  • RTH258
    Diabetic Retinopathy
    Others Phase 3 2025 VEGF inhibitor
    Supplementary Indication
  • SEG101
    Sickle cell disease, pediatrics
    In-market Brands and Global Health Phase 2 ≥ 2027 P-selectin inhibitor
    Supplementary Indication
  • TIN816
    Acute kidney injury
    Cardiovascular Phase 2 ATP modulator
    Lead Indication
  • TNO155
    Solid tumors (single agent)
    Oncology: Solid Tumors Phase 2 SHP2 inhibitor
    Lead Indication
  • TQJ230
    Secondary prevention of cardiovascular events in patients with elevated levels of Lipoprotein(a) (CVRR-Lp(a))
    Cardiovascular Phase 3 2025 ASO targeting Lp(a)
    Lead Indication
  • VAY736
    Lupus Nephritis
    Immunology Phase 3 ≥ 2027 BAFF-R inhibitor, ADCC-mediated B-cell depletor
    New Indication
  • VAY736
    Systemic lupus erythematosus (SLE)
    Immunology Phase 3 ≥ 2027 BAFF-R inhibitor, ADCC-mediated B-cell depletor
    New Indication
  • VAY736
    Sjoegren's syndrome
    Immunology Phase 3 2026 BAFF-R inhibitor, ADCC-mediated B-cell depletor
    Lead Indication

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.


This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.